118A>G AND IVS2+691G>C POLYMORPHISMS OF OPRM1 GENE HAVE NO INFLUENCE ON COLD-PAIN SENSITIVITY AMONG HEALTHY OPIOID-NAIVE MALAY MALES by Zahari, Zalina et al.
 
 
118A>G AND IVS2+691G>C POLYMORPHISMS OF OPRM1 GENE HAVE NO INFLUENCE ON 
COLD-PAIN SENSITIVITY AMONG HEALTHY OPIOID-NAIVE MALAY MALES 
Original Article 
 
ZALINA ZAHARI1,2*, LEE CHEE SIONG3, LEE YEONG YEH4, MUSLIH ABDULKARIM IBRAHIM2,5, NURFADHLINA 
MUSA2, MD AZHAR MOHD YASIN2,6, TAN SOO CHOON2, NASIR MOHAMAD2,7, RUSLI ISMAIL2,8 
1Department of Pharmacy, Hospital Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia, 2Pharmacogenetics and Novel Therapeutics 
Cluster, Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia (USM), Kubang Kerian, Kelantan, Malaysia, 
3Department of Emergency Medicine, School of Medical Sciences, Universiti Sains Malaysia (USM), Kubang Kerian, Kelantan, Malaysia, 4School of 
Medical Sciences, Universiti Sains Malaysia (USM), Kubang Kerian, Kelantan, Malaysia, 5Department of Pharmacology and Toxicology, College of 
Pharmacy, Hawler Medical University, Hawler, Iraq, 6Department of Psychiatry, School of Medical Sciences, Universiti Sains Malaysia (USM), 
Kubang Kerian, Kelantan, Malaysia, 7Faculty of Medicine & Health Sciences, Universiti Sultan Zainal Abidin, Kuala Terengganu, Terengganu, 
Malaysia, 8
 Received: 23 Dec 2015 Revised and Accepted: 17 May 2016 
Centre of Excellence for Research in AIDS (CERiA), University of Malaya, Kuala Lumpur, Malaysia. 
Email: zzalina@usm.my     
ABSTRACT 
Objective: Common polymorphisms of the mu-type opioid receptor (OPRM1) including 118A>G and IVS2+691G>C may affect experimental pain 
responses in healthy subjects, and the effect could be ethnic-dependent. The aim of this study was to investigate the influence of these OPRM1 
polymorphisms on cold-pressor pain responses among healthy opioid-naive Malay males.  
Methods: Pain-threshold, pain-tolerance, and pain-intensity in response to the cold pressor test (CPT) were measured in healthy opioid-naive 
Malay males. DNA was extracted from the collected venous blood before PCR-genotyping. Repeated measure analysis of variance (RM-ANOVA) was 
used to compare CPT responses and OPRM1 polymorphisms (118A>G and IVS2+691G>C) according to their genotypes and allelic additive models, 
genotype dominant and recessive models, haplotypes, and diplotypes.  
Results: A total of 152 participants were recruited. Both 118A>G and IVS2+691G>C polymorphisms were not associated with cold-pressor pain-
threshold, pain-tolerance and pain-intensity despite using genotypes and allelic additive models and genotype dominant and recessive models (all 
p>0.05). Likewise, there were no significant associations between haplotypes and diplotypes for the 118A>G and IVS2+691G>C polymorphisms and 
the three cold-pain responses (all p>0.05).  
Conclusion: The common OPRM1 polymorphisms (i.e., 118A>G and IVS2+691G>C), are not associated with cold-pressor pain responses in healthy 
opioid-naive Malay males. However, this may be unique for this particular ethnicity. Other polymorphisms may be more relevant for this 
population, and this should be further investigated. 
Keywords: Cold pressor test (CPT), Mu-type opioid receptor (OPRM1), Opioid receptor, mu 1 gene (OPRM1), Pain-threshold, Pain-tolerance, Pain-
intensity, Opioid-naive, Male, Malays 
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INTRODUCTION  
The mu-type opioid receptor (OPRM1) is a major opioid receptor in 
human. Together with the δ-opioid receptor (DOR) and κ-opioid 
receptor (KOR), they are the binding sites for endogenous opioid 
peptides [1, 2] and exogenous opioids, including methadone [3]. 
Studies have shown that activation of the OPRM1 system was 
associated with reductions in the sensory and affective ratings of 
pain experience [4]. Variability in pain modulation and inter-
individual differences in treatment outcomes with opioid-based 
analgesic therapy may be a result of variations in the OPRM1 gene 
[5-12]. A previous study in healthy males found that a low OPRM1 
binding potential in the striatum was associated with a low cold 
pain-threshold [13]. Thus, it is hypothesized that individuals with 
low OPRM1 binding potential have low receptor density, and 
consequently, low level of OPRM1-mediated suppression of pain 
pathways, leading to increased experimental pain sensitivity [13]. 
The 118A>G polymorphism being the most common variation of the 
OPRM1 gene is found to exert influences on experimental pain 
responses in healthy subjects [14, 15] but the effect may be ethnic-
dependent [16]. Individuals with 118G allele but not the wild-type 
allele exhibited lower sensitivity to pressure pain (or higher 
pressure pain-threshold) [14]. Other less common but important 
polymorphisms of the OPRM1 gene have included IVS2+31G>A 
(dbSNP rs9479757) and IVS2+691G>C (dbSNP rs2075572). While 
IVS2+31G>A polymorphism was associated with a higher pressure 
pain-threshold in healthy adult females [17] but IVS2+691G>C 
polymorphism has not been previously studied. 
Southeast Asia is a highly populated and culturally diverse region 
with ethnic Malays consisted the largest population group, mainly 
populating countries including Malaysia, Indonesia and southern 
part of the Philippines. Males of ethnic Malays consisted the majority 
of opioid-dependent patients on methadone treatment in Malaysia, 
but it is not known whether OPRM1 polymorphisms influence the 
inter-individual variations in pain responses. The current study 
aimed to investigate the influence of common OPRM1 
polymorphisms (i.e., 118A>G and IVS2+691G>C) on cold-pressor 
pain responses among healthy opioid-naive Malay males. Results of 
this study would be helpful to determine whether these 
polymorphisms are suitable for further studies in opioid-dependent 
patients.  
MATERIALS AND METHODS 
Study participants 
Participants comprised 152 opioid-naive Malay males between 18 
and 63 y of age (mean = 27.46 y). They were randomly sampled from 
within the hospital compound. The participants consisted of staffs 
and students. Written informed consents were obtained from each 
participant prior to enrolment. This study was part of a larger study 
to investigate the genetic factors that may influence cold-pressor pain 
responses in opioid-dependent patients on methadone treatment 
(National Medical Research Register (NMRR) number: NMRR-13-524-
16614). It was approved by the Human Research Ethics Committee 
(HREC), Universiti Sains Malaysia (USM) in Kelantan, Malaysia 
(Reference number: USMKK/PPP/JEPeM (253.3) [14]. 
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Assessment of study participants 
Urine drug screens for morphine, tetra-hydrocannabinol, 
amphetamines and benzodiazepines using drugs of abuse rapid test, 
F. A. C. T. S TM
Cold pressor test (CPT) 
 4 in 1 Combo Dipcard Rapid Test (MOR/ THC/ 
AMP/BZO) (Scientifacts Sdn. Bhd., Malaysia) were performed for 
each participant twice in one week prior to CPT. Only subjects with 
two consecutive negative urine tests were allowed to continue with 
the study. A history of analgesics consumption within 72 h prior to 
study entry and a positive history of any painful conditions were 
exclusion criteria. Subjects with any known acute or chronic 
medical, surgical and psychiatric illnesses that required concurrent 
medical, surgical or psychiatric therapy and severe cognitive 
impairment which might interfere with pain assessments and/or 
communication were also excluded from the study.  
The CPT method utilized in the current study was adapted from 
Chen et al. (1989) and Compton et al. (2001) and had been described 
else where [20]. Briefly, the CPT apparatus consisted of a 48-quart 
cool box filled with a mixture of two-thirds crushed ice and one-
third tap water. A constant temperature of 0–2 °C was maintained 
by adding ice intermittently. The non-dominant hand and forearm 
of the participant would be placed in the ice bath with their palm 
flat at the bottom of the box, with ice water covered the hand and 
approximately 10 cm of the forearm. The test was truncated at 300 
s, since after this time, the numbness would set in and the pain 
diminished [19, 21, 22]. Pain-threshold was defined as the first 
experience of pain that can be identified, pain-tolerance as the 
time elapsed when the participant had to withdrew his hand (i.e., 
the most severe pain that a subject was willing to tolerate) and 
pain-intensity as the maximal pain experienced during test on a 
visual analogue scale (VAS; 0–100). We examined the cold-pressor 
responses six times over a 24 h period [i.e., at 0 h (at about 8.00 
am), and at 2, 4, 8, 12, and 24 h after the first CPT], in order to 
minimise the possible diurnal variations in cold-pressor pain 
response [23].  
PCR genotyping for 118A>G, IVS2+31G>A and IVS2+691G>C 
polymorphisms of OPRM1 
Venous blood (2.5 ml) samples for genotyping were collected in 
tubes containing sodium citrate and the blood samples were stored 
at–20 °C until further processing. Genomic DNA was extracted from 
the unclotted venous blood using QIAamp DNA Blood Mini Kit 
(Qiagen Gmbh, Hilden, Germany) according to the manufacturer’s 
instructions. The quantity and quality of the extracted genomic DNA 
were determined on the NanoDrop
A two-step PCR method for simultaneous OPRM1 and CYP2B6 
genotyping were developed by the Institute for Research in 
Molecular Medicine (INFORMM) and this had been validated for 
reproducibility and specificity through direct sequencing [24]. 
All PCR reactions were performed in standard 0.2 ml Eppendorf 
PCR tubes and carried out in a volume of 25 µl comprising buffer 
[10 mM Tris-HCl (pH 8.0), 50 mM KCl, 1 mM EDTA, 0.1% Triton 
X-100, 50.0% glycerol (v/v)]. The reactions were performed on 
the Applied Biosystems
ND-1000 Spectrophotometer 
(NanoDrop Technologies, Inc. Wilmington, USA) with measurements 
performed at 260 and 280 nm.  
 Veriti
Briefly, the first step PCR (‘Set A’) was performed using specifically 
designed primers (table 1) to isolate out regions of interest that contain 
the relevant OPRM1 polymorphisms (118A>G, IVS2+31G>A and 
IVS2+691G>C) that were later used for the second allele-specific PCR to 
avoid amplifications of similar sequences in the human genome that may 
be located outside the gene. PCR reaction mixture for Set A contained 1.0 
U of Biotool
 96-Well Thermal Cycler 
(Applied Biosystems, Carlsbad, CA, USA).  
 DNA Taq Polymerase (Biotools, Biotechnological & Medical 
Laboratories, SA, Madrid, Spain), 2.0 mM MgCl2
Data and statistical analysis 
, 0.2 mM dNTPs 
(Biotools, Biotechnological & Medical Laboratories, SA, Madrid, Spain) 
and 0.10–0.25 µM of the primers (Invitrogen, Waltham, MA, USA). The 
cycling conditions were optimized for Set A. Ten microliters of the first 
PCR products of Set A were analyzed using 2.0% agarose gel (Promega 
Corporation, Madison, WI, USA) and 1 x TBE (Tris, Borate, EDTA) at 100 
V for 60 min. Two microliters of the diluted first step PCR products of Set 
A were used as a template for detection of wild-type or mutant-type 
alleles in second step PCR.  The second step PCR reaction was carried 
out using identical reaction mixture described for the first step PCR, 
with the exceptions of primer concentrations shown in table 1. The 
cycling conditions were again optimized and ten microliters of the 
second PCR products were again analyzed using 2.0% agarose gel 
(Promega Corporation, Madison, WI, USA) and 1 x TBE at 100 V for 
60 min.  
The sample size was calculated prior to recruitment based on the 
Cohen sample size table [25], using medium population effect size 
(ES) at the power of 0.80 for an α value of 0.05. Samples of 64 alleles 
or subjects per group were required for comparisons of means of 
two groups (under the allelic additive model, genotype dominant 
and recessive model).  
Genotyping data were analyzed using the population genetic data 
analytical program, Golden Helix SNP and Variation Suite 7 (SVS 7, 
version 7.3.1; Golden Helix Inc., Bozeman, MT, USA) based on an 
expectation-maximization (EM) algorithm for the following 
procedures: (a) the calculation of OPRM1 alleles and genotypes 
frequencies; (b) the estimation of heterozygosity in each 
polymorphism in Hardy-Weinberg proportion; (c) the estimation of 
maximum-likelihood haplotype frequency.  
  
Table 1: OPRM1 primers used for allele-specific multiplex PCR of OPRM1 118A>G (dbSNP rs1799971), IVS2+31G>A (dbSNP rs9479757) 
and IVS2+691G>C (dbSNP rs2075572) 
PCR Primer Sequence (5’–3’) Fragment size (bp) [Primer] (µM) 
First PCR Set A µ EX1 FW aaa gtc tcg gtg ctc ctg gct 420 0.10 
 µ EX1 RV tgg gag tta ggt gtc tct ttg ta  0.10 
 µ INT2 FW tag att tcc gta ctc ccc gaa 1020 0.20 
 µ INT2 RV cgc aag atc atc agt cca tag   0.20 
Second PCR Set 1    
Common primer µ EX1 RV tgg gag tta ggt gtc tct ttg ta  0.25 
Wild-type primers  µ 118 A FW caa ctt gtc cca ctt aga tgg ca 267 0.25 
Mutant-type primers µ 118 G FW caa ctt gtc cca ctt aga tgg cg  0.25 
Second PCR Set 2   
Common primer µ INT2 RV cgc aag atc atc agt cca tag   0.15 
Wild-type primers µ 691G FW gct ctg gtc aag gct aaa aat g 240 0.15 
Mutant-type primers µ 691C FW gct ctg gtc aag gct aaa aat c  0.15 
Second PCR Set 3   
Common primer µ INT2 FW tag att tcc gta ctc ccc gaa  0.25 
Wild-type primers µ 31G RV aac ata tca ggc tgt gaa ccc 162 0.25 
Mutant-type primers µ 31A RV aac ata tca ggc tgt gaa cct  0.25 
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RESULTS  
Distributions of OPRM1 polymorphisms 
The 118A/G, IVS2+31G>A and IVS2+691G>C allele of OPRM1 gene 
were successfully amplified from all 152 subjects. Genotyping 
analysis revealed that one subject possessed polymorphism in the 
IVS2+31 locus of the OPRM1 gene (table 2). The genotype at the 
locus was heterozygous for IVS2+31A allele (IVS2+31G>A). The 
distribution of OPRM1 118A>G, IVS2+31G>A and IVS2+691G>C 
genotypes were in Hardy-Weinberg equilibrium (HWE) (p>0.129). 
Assuming a mutant-type allele was a high-risk allele, genotype 
frequencies under the dominant and recessive models were determined. 
The most likely haplotype pair or diplotype in each individual was 
estimated and the haplotype frequency distributions were obtained with 
an expectation-maximum (EM) algorithm (table 2).  
The lack of associations of 118A>G and IVS2+691G>C 
polymorphisms with pain sensitivity  
Due to low frequency of IVS2+31G>A polymorphism in the current 
study samples, further, analyses were not performed for this 
polymorphism, and thus, haplotype patterns were constructed 
from the two polymorphisms of OPRM1 (118A>G and IVS2+ 
691G>C).  
The 118A>G and IVS2+691G>C polymorphisms were not associated 
with pain-threshold, pain-tolerance and pain-intensity despite using 
genotypes and allelic additive models and genotype dominant and 
recessive models (all p>0.05) (table 3, 4 and 5). Likewise, there were 
no significant associations between haplotypes and diplotypes for 
the 118A>G and IVS2+691G>C polymorphisms and the three cold-
pain responses (all p>0.05) (table 3, 4 and 5 
 
Table 2: Allele, genotype, haplotype and diplotype distributions for the three screened polymorphisms of OPRM1 in opioid-naive Malay 
males 
Polymorphism   N Frequency (%) 95% CI of frequency HWE p value 
    Lower limit  Upper limit  
118A>G       
Genotype (N = 152) AA 35 23.0 16.3 29.7 0.748 
 AG 74 48.7 40.8 56.6  
 GG 43 28.3 21.1 35.5  
Allele (N = 304) A 144 47.4 41.8 53.0  
 G 160 52.6 47.0 58.2  
Dominant model AA 35 23.0 16.3 29.7  
 AG+GG 117 77.0 70.3 83.7  
Recessive model AA+AG 109 71.7 64.5 78.9  
 GG 43 28.3 21.1 35.5  
IVS2+691G>C       
Genotype (N = 152) GG 1 0.7 0.0 2.0 0.129 
 GC 45 29.6 22.3 36.9  
 CC 106 69.7 62.4 77.0  
Allele (N = 304) G 47 15.5 11.4 19.6  
 C 257 84.5 80.4 88.6  
Dominant model GG 1 0.7 0.0 2.0  
 GC+CC 151 99.3 98.0 100.0  
Recessive model GG+GC 46 30.3 23.0 37.6  
 CC 106 69.7 62.4 77.0  
IVS2+31G>A       
Genotype (N = 152) GG 151 99.3 98.0 100.0 1.000 
 GA 1 0.7 0.0 2.0  
 AA 0 0.0 0.0 0.0  
Allele (N = 304) G 303 99.7 99.1 100.0  
 A 1 0.3 0.0 0.9  
Dominant model GG 151 99.3 98.0 100.0  
 GA+AA 1 0.7 0.0 2.0  
Recessive model GG+GA 152 100.0 100.0 100.0  
 AA 0 0.0 0.0 0.0  
Haplotype (N = 304)  a      
1.  GCG 158 52.0 46.4 57.6  
2.  ACG 99 32.6 27.3 37.9  
3.  AGG 44 14.5 10.5 18.5  
4.  GGG 2 0.7 0.0 1.6  
5.  AGA 1 0.3 0.0 0.9  
Diplotype (N = 152)       
1.  ACG/GCG 51 33.6 26.1 41.1  
2.  GCG/GCG 41 27.0 19.9 34.1  
3.  GCG/AGG 23 15.1 9.4 20.8  
4.  ACG/AGG 19 12.5 7.2 17.8  
5.  ACG/ACG 14 9.2 4.6 13.8  
6.  GCG/GGG 2 1.3 0.0 3.1  
7.  AGA/ACG 1 0.7 0.0 2.0  
8.  AGG/AGG 1 0.7 0.0 2.0  
N, number of subject/allele/haplotype/diplotype; CI, confidence interval; HWE, Hardy-Weinberg equilibrium, a
 
Haplotype patterns were constructed 
from the three screened polymorphisms of OPRM1 (118A>G, IVS2+691G>C and IVS2+31G>A) 
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Table 3: Influences of 118A>G and IVS2+691G>C polymorphisms on pain-threshold in opioid-naive Malay males 
Polymorphism  N Mean#  95% CI F-stat. (df) p value* a 
   Lower limit  Upper limit   
118A>G       
Genotype (N = 152)       
AA 35 62.40 40.83 83.98 0.73 (2) 0.483 
AG 74 48.88 34.05 63.72   
GG 43 45.69 26.22 65.15   
Allele (N = 304)       
A 144 55.46 44.91 66.01 1.26 (1) 0.263 
G 160 47.16 37.15 57.17   
Dominant model       
AA 35 62.40 40.90 83.91 1.40 (1) 0.238 
AG+GG 117 47.71 35.95 59.47   
Recessive model       
AA+AG 109 53.22 41.00 65.45 0.42 (1) 0.518 
GG 43 45.69 26.22 65.15   
IVS2+691G>C       
Genotype (N = 152)       
GG 1 20.90 -107.10 148.89 0.29 (2) 0.747 
GC 45 46.40 27.32 65.48   
CC 106 53.37 40.93 65.80   
Allele (N = 304)       
G 47 45.32 26.83 63.81 0.45 (1) 0.504 
C 257 52.15 44.24 60.06   
Dominant model       
GG 1 20.90 -106.82 148.61 0.22 (1) 0.640 
GC+CC 151 51.29 40.90 61.68   
Recessive model       
GG+GC 46 45.85 27.03 64.67 0.43 (1) 0.511 
CC 106 53.37 40.97 65.76   
Haplotype (N = 304)  b      
GC 158 47.40 37.32 57.48 0.94 (3) 0.422 
AC 99 59.73 46.99 72.46   
AG 45 46.06 27.18 64.95   
GG 2 28.55 -61.04 118.14     
GC 158 47.40 37.33 57.46 1.34 (2) 0.263 
AC 99 59.73 47.01 72.44   
Combined AG and GG 47 45.32 26.86 63.77     
GC 158 47.40 37.32 57.47 1.08 (1) 0.299 
Not GC 146 55.09 44.61 65.57   
AC 99 59.73 47.03 72.42 2.66 (1) 0.104 
Not AC 205 46.92 38.10 55.74   
AG 45 46.06 27.16 64.96 0.32 (1) 0.571 
Not AG 259 51.97 44.09 59.84   
Diplotype (N = 152)       
AC/GC 51 55.81 37.92 73.71 0.76 (4) 0.554 
GC/GC 41 46.52 26.56 66.48   
GC/AG 23 33.51 6.86 60.16   
AC/AG 20 63.01 34.43 91.59   
Othersc 17   57.71 26.71 88.71     
AC/GC 51 55.81 37.94 73.69 0.41 (1) 0.523 
Not AC/GC 101 48.71 36.01 61.41   
GC/GC 41 46.52 26.58 66.46 0.28 (1) 0.597 
Not GC/GC 111 52.78 40.66 64.90   
GC/AG 23 33.51 7.04 59.98 2.03 (1) 0.156 
Not GC/AG 129 54.23 43.05 65.40   
AC/AG 20 63.01 34.51 91.52 0.79 (1) 0.377 
Not AC/AG 132 49.29 38.19 60.38   
N, number of subject/allele/haplotype/diplotype; CI, confidence interval, # Means for cold pain-threshold (seconds); * p-value is significant at<0.05, 
aRepeated measured ANOVA between-group analysis was applied, bHaplotype patterns were constructed from the two polymorphisms of OPRM1 
(118A>G and IVS2+691G>C), c
 
Diplotype with frequency less than 10.0% were pooled under ‘Others’ (included AC/AC, GC/GG, AG/AG) 
Table 4: Influences of 118A>G and IVS2+691G>C polymorphisms on pain-tolerance in opioid-naive Malay males 
Polymorphism  N Mean#  95% CI F-stat. (df) p value* a 
   Lower limit  Upper limit   
118A>G       
Genotype (N = 152)       
AA 35 73.92 50.24 97.60 0.72 (2) 0.491 
AG 74 57.35 41.06 73.63   
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GG 43 58.02 36.66 79.39   
Allele (N = 304)       
A 144 65.40 53.82 76.99 0.90 (1) 0.344 
G 160 57.71 46.72 68.70   
Dominant model       
AA 35 73.92 50.32 97.52 1.44 (1) 0.232 
AG+GG 117 57.60 44.69 70.51   
Recessive model       
AA+AG 109 62.67 49.24 76.10 0.13 (1) 0.717 
GG 43 58.02 36.64 79.41   
IVS2+691G>C       
Genotype (N = 152)       
GG 1 29.11 -111.47 169.68 0.20 (2) 0.817 
GC 45 57.62 36.66 78.57   
CC 106 63.25 49.59 76.90   
Allele (N = 304)       
G 47 56.41 36.10 76.71 0.27 (1) 0.602 
C 257 62.26 53.58 70.94   
Dominant model       
GG 1 29.11 -111.09 169.30 0.21 (1) 0.649 
GC+CC 151 61.57 50.16 72.98   
Recessive model       
GG+GC 46 57.00 36.33 77.67 0.25 (1) 0.619 
CC 106 63.25 49.63 76.86   
Haplotype (N = 304)  b      
GC 158 57.98 46.90 69.06 0.65 (3) 0.586 
AC 99 69.09 55.10 83.09   
AG 45 57.28 36.52 78.05   
GG 2 36.63 -61.85 135.11   
GC 158 57.98 46.91 69.04 0.89 (2) 0.412 
AC 99 69.09 55.12 83.07   
Combined AG and GG 47 56.40 36.12 76.69   
GC 158 57.98 46.91 69.04 0.75 (1) 0.387 
Not GC 146 65.01 53.50 76.52   
AC 99 69.09 55.14 83.05 1.77 (1) 0.185 
Not AC 205 57.62 47.92 67.32   
AG 45 57.28 36.53 78.04 0.17 (1) 0.676 
Not AG 259 62.06 53.41 70.71   
Diplotype (N = 152)       
AC/GC 51 63.93 44.27 83.60 0.68 (4) 0.609 
GC/GC 41 59.07 37.13 81.00   
GC/AG 23 42.75 13.46 72.03   
AC/AG 20 76.82 45.42 108.23   
Othersc 17   66.12 32.05 100.18   
AC/GC 51 63.93 44.30 83.57 0.10 (1) 0.751 
Not AC/GC 101 60.05 46.10 74.01   
GC/GC 41 59.07 37.16 80.97 0.06 (1) 0.810 
Not GC/GC 111 62.20 48.89 75.51   
GC/AG 23 42.75 13.67 71.82 1.89 (1) 0.172 
Not GC/AG 129 64.67 52.40 76.95   
AC/AG 20 76.82 45.57 108.08 1.10 (1) 0.296 
Not AC/AG 132 59.01 46.85 71.18   
N, number of subject/allele/haplotype/diplotype; CI, confidence interval, # Means for cold pain-tolerance (seconds); * p-value is significant at<0.05, 
aRepeated measured ANOVA between-group analysis was applied, bHaplotype patterns were constructed from the two polymorphisms of OPRM1 
(118A>G and IVS2+691G>C), c
 
Diplotype with frequency less than 10.0% were pooled under ‘Others’ (included AC/AC, GC/GG, AG/AG) 
Table 5: Influences of 118A>G and IVS2+691G>C polymorphisms on pain-intensity scores in opioid-naive Malay males 
Polymorphism  N Mean#  95% CI F-stat. (df) p value* a 
   Lower limit  Upper limit   
118A>G       
Genotype (N = 152)       
AA 35 65.24 60.55 69.93 0.79 (2) 0.457 
AG 74 65.05 61.82 68.27   
GG 43 61.94 57.71 66.17   
Allele (N = 304)       
A 144 65.14 62.84 67.43 1.20 (1) 0.274 
G 160 63.38 61.20 65.55   
Dominant model       
AA 35 65.24 60.54 69.93 0.24 (1) 0.623 
AG+GG 117 63.90 61.33 66.47   
Recessive model       
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AA+AG 109 65.11 62.46 67.76 1.58 (1) 0.211 
GG 43 61.94 57.72 66.16   
IVS2+691G>C       
Genotype (N = 152)       
GG 1 66.67 38.77 94.56 0.02 (2) 0.984 
GC 45 64.11 59.95 68.27   
CC 106 64.23 61.52 66.94   
Allele (N = 304)       
G 47 64.22 60.19 68.25 0.00 (1) 0.996 
C 257 64.21 62.49 65.93   
Dominant model       
GG 1 66.67 38.86 94.47 0.03 (1) 0.861 
GC+CC 151 64.19 61.93 66.46   
Recessive model       
GG+GC 46 64.17 60.07 68.27 0.00 (1) 0.980 
CC 106 64.23 61.53 66.93   
Haplotypeb   (N = 304)      
GC 158 63.52 61.33 65.72 0.89 (3) 0.448 
AC 99 65.30 62.53 68.07   
AG 45 64.78 60.67 68.89   
GG 2 51.67 32.17 71.16   
GC 158 63.52 61.33 65.72 0.49 (1) 0.613 
AC 99 65.30 62.53 68.08   
Combined AG and GG 47 64.22 60.19 68.25   
GC 158 63.52 61.33 65.72 0.79 (1) 0.374 
Not GC 146 64.95 62.67 67.24   
AC 99 65.30 62.53 68.07 0.89 (1) 0.345 
Not AC 205 63.68 61.76 65.61   
AG 45 64.78 60.66 68.89 0.09 (1) 0.769 
Not AG 259 64.11 62.40 65.83   
Diplotype (N = 152)       
AC/GC 51 65.10 61.18 69.02 0.23 (4) 0.922 
GC/GC 41 62.44 58.07 66.81   
GC/AG 23 64.93 59.09 70.77   
AC/AG 20 64.42 58.15 70.68   
Othersc 17   64.61 57.82 71.40   
AC/GC 51 65.10 61.21 68.99 0.31 (1) 0.581 
Not AC/GC 101 63.76 61.00 66.53   
GC/GC 41 62.44 58.11 66.77 0.90 (1) 0.346 
Not GC/GC 111 64.86 62.23 67.50   
GC/AG 23 64.93 59.13 70.72 0.07 (1) 0.791 
Not GC/AG 129 64.08 61.64 66.53   
AC/AG 20 64.42 58.20 70.63 0.00 (1) 0.944 
Not AC/AG 132 64.18 61.76 66.60   
N, number of subject/allele/haplotype/diplotype; CI, confidence interval, # Means for cold pain-intensity scores; * p value is significant at<0.05, 
aRepeated measured ANOVA between-group analysis was applied, bHaplotype patterns were constructed from the two polymorphisms of OPRM1 
(118A>G and IVS2+691G>C), c
 
Diplotype with frequency less than 10.0% were pooled under ‘Others’ (included AC/AC, GC/GG, AG/AG) 
DISCUSSION  
The allelic frequencies of OPRM1 polymorphisms in the present 
study were similar to previous reports from Singapore [118G = 45 
(95% CI 39.0, 51.1) and IVS2+691C = 79.5 (95% CI 74.7, 84.4)] [27] 
with the exception of IVS2+31G allele. The frequency of IVS2+31G 
allele in our study was similar to other Asian populations for 
example, in the Taiwan population, the reported frequency was 
2.8% (95% CI 0.1, 5.5)][17]. 
Among the identified polymorphisms within the OPRM1 gene, 
118A>G polymorphism is the most frequently studied in the 
literature but the evidence is, unfortunately, inconsistent with 
regards to its association with pain sensitivity to various 
experimental stimuli [14, 15, 17, 28, 29]. In the present study, 
118A>G and IVS2+691G>C polymorphisms were not associated with 
cold-pain responses among the Malay males. Only one published 
study which was similar to ours where the same cold-pain technique 
was used but in the Japanese subjects [29]. Although the association 
of cold pain sensitivity with vs. without 118G allele was significant in 
this Japanese population but the response difference was only one 
second (7%) [29]. Tan, et al. (2009) found an association between 
118A>G genotypes and pain-intensity among the non-laboring 
Chinese women undergoing caesarean section but again no such 
association was found among the Malays. This suggests that 
ethnicity may be a major determinant for the role of 118A>G 
polymorphism in pain sensitivity [17]. 
There are other explanations to our negative results. There may be 
differences in experimental pain models (for example electrical or 
heat pain rather than cold), gender, study sample size, frequency of 
mutant-type 118G allele and whether study participants had been 
pre-medicated with centrally acting agents. Furthermore, the clinical 
impact of 118A>G polymorphism in pain sensitivity remains 
controversial. An earlier in vitro functional study has demonstrated 
that 118G allele altered the β-endorphin binding affinity [31]. 
Moreover, a recent study did not find any marked functional differences 
between variant and wild-type receptors in terms of morphine, 
morphine-6-glucuronide and β-endorphin binding affinities and 
potencies [32]. They also found both the variant receptor and wild-type 
receptors exhibited robust receptor internalization and they showed 
similar desensitization time courses [32]. But in vitro studies showed 
that there was a lower expression of the receptor protein corresponding 
to the 118G allele [32, 33]. In addition, it is likely that variations of other 
candidate genes may be more relevant in our population including 
CYP2D6, ABCB1, COMT, and other opioid receptor genes including 
OPRD1 and OPRK1 genes [34]. 
Some study limitations need to be highlighted. Firstly, we only 
studied Malay males, but this was to control for gender effect on 
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pain sensitivity [35-41] besides the fact that Malay males were the 
majority of opioid-dependent patients on methadone treatment in 
Malaysia. Secondly, our study did not evaluate for psychological 
distress including anxiety or stress which might influence pain 
perception [42]. Lastly, the sample size was inadequate for post-hoc 
studies and it was underpowered because the observed numbers of 
subjects with AA and GG genotypes were small. Thirdly, only one 
pain modality (i.e., cold-pain) was studied.  
CONCLUSION  
The current study indicates that the common OPRM1 
polymorphisms (i.e., 118A>G and IVS2+691G>C) are not associated 
with cold-pressor pain-threshold, tolerance and intensity in healthy 
opioid-naive Malay males. However, this may be unique for this 
particular ethnicity. Other polymorphisms may be more relevant for 
this population and this should be further investigated. 
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